Crossmark

Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus

Crossref DOI link: https://doi.org/10.1007/s40261-020-00978-4

Published Online: 2020-10-21

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yao, Zhenling https://orcid.org/0000-0002-4271-2837
Loggia, Laura

Fink, Damien

Chevrier, Marc

Marciniak, Stanley

Sharma, Amarnath

Xu, Zhenhua
Funding

Funding for this research was provided by:

Janssen Research and Development
License Information

Text and Data Mining valid from 2020-10-21

Version of Record valid from 2020-10-21
More Information

Article History

Accepted: 7 October 2020

First Online: 21 October 2020

Declarations

:

: Janssen Research & Development, LLC provided funding for this study.

: Yao Z, Loggia L, Fink D, Chevrier M, Marciniak S, Sharma A, and Xu Z are employees of Janssen Research & Development, LLC, a wholly owned subsidiary of Johnson & Johnson, Inc. Yao Z, Loggia L, Fink D, Chevrier M, Marciniak S, Sharma A, and Xu Z may own stocks in Johnson & Johnson, Inc. Medical writing support from Synchrogenix was paid for by Janssen Research & Development, LLC.

: All participants provided informed consent to participate in this study.

: All authors consent that they approve the manuscript for submission.

: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. is available at . As noted in this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at .

: Code is available upon request.

Document is current

Any future updates will be listed below